Ikena Oncology Investor Relations Material

Ikena Oncology is a U.S.-based biopharmaceutical company focused on developing innovative therapies targeting cancer and other immune-related diseases. The company's research centers on molecular mechanisms that drive tumor growth and immune evasion, with a focus on precision oncology and immuno-oncology approaches. Ikena’s pipeline includes treatments aimed at targeting key signaling pathways involved in cancer progression, with therapies designed to offer new options for patients with difficult-to-treat cancers. The company is headquartered in Boston, Massachusetts, and its shares are listed on NASDAQ.